Saudi Arabia

The Saudi Food and Drug Authority (SFDA) is the primary national regulatory body responsible for overseeing the safety, efficacy, and quality of health products in Saudi Arabia, including pharmaceuticals, medical devices, diagnostics, and digital health solutions. Established under Royal Decree M/55 in 2003, the SFDA operates under a comprehensive legislative framework that includes the Drug and Pharmacy Law and subsequent implementing regulations specific to each product category. The general approval process requires manufacturers or their local authorized representatives to submit a formal registration application through the SFDA's unified electronic portal, GHAD for devices or the Drug Registration System for pharmaceuticals, followed by technical review, conformity assessment, and, where required, local or international laboratory testing. Post-market surveillance obligations and periodic renewal requirements apply to all registered products.

Applications to the SFDA must be submitted through a licensed Saudi local authorized representative (LAR), which is mandatory for all foreign manufacturers. The SFDA accepts dossiers prepared in accordance with the Common Technical Document (CTD) format for pharmaceuticals and the Global Medical Device Nomenclature (GMDN) classification system aligned with IMDRF guidelines for medical devices. In vitro diagnostic devices are regulated under a separate risk-based classification framework. Notably, the SFDA has pursued significant reforms in recent years as part of Vision 2030, including accelerated review pathways for innovative and priority products, mutual recognition agreements with select stringent regulatory authorities such as the US FDA, EMA, and Health Canada, and expanded reliance procedures that allow approvals from recognized reference agencies to expedite local registration timelines.

Public procurement of health products in Saudi Arabia is predominantly centralized through the Ministry of Health (MOH), which operates the largest public healthcare network in the country. The National Unified Procurement Company (NUPCO), established in 2008 and now majority-owned by the Public Investment Fund (PIF), serves as the central purchasing and logistics entity for MOH facilities, consolidating tenders for pharmaceuticals, medical devices, diagnostics, and consumables to achieve economies of scale. Large-scale national tenders are managed through the Government Tenders and Procurement Law framework, overseen by the National Competitiveness Center (NCC), with contracts typically awarded following open competitive bidding. Beyond the MOH, other government entities such as the Ministry of National Guard Health Affairs, the Saudi Aramco Medical Services, and the armed forces medical services each conduct independent procurement processes, adding additional public-sector channels for suppliers.

The private healthcare sector in Saudi Arabia is substantial and growing rapidly, driven by Vision 2030 healthcare privatization initiatives and mandatory health insurance regulations. Private hospital groups, pharmacy chains, and diagnostic laboratory networks procure independently through direct commercial negotiations with distributors and manufacturers, representing a significant parallel market channel. Saudi Arabia does not rely on major donor-funded procurement mechanisms such as UNICEF Supply Division, the Global Fund, or Gavi, as it is a high-income country, but it participates in Gulf Cooperation Council (GCC) joint procurement initiatives coordinated through the GCC Standardization Organization (GSO). Local manufacturing is actively incentivized under the National Industrial Development and Logistics Program (NIDLP) and Vision 2030, with preferential scoring in public tenders for products manufactured domestically, and the government has established the Taqnia Health cluster and various public-private partnerships to attract in-country production and technology transfer arrangements.